Welcome to our dedicated page for Nasus Pharma Ltd. SEC filings (Ticker: NSRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nasus Pharma Ltd. (NSRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Nasus Pharma files reports with the U.S. Securities and Exchange Commission that include current information on its clinical programs, financial condition, governance, and material agreements.
Nasus Pharma submits current reports on Form 6-K, which have covered topics such as condensed unaudited interim financial statements and management’s discussion and analysis for specified periods, leadership appointments, clinical trial milestones, and collaboration agreements. For example, Form 6-K reports have described the appointment of an Executive Vice President and Chief Financial Officer, the initiation of a Phase 2 clinical study of NS002 with first participant dosed, and expanded agreements with Aptar France S.A.S. and AptarGroup, Inc. to support the intranasal epinephrine program.
Filings also document capital markets events, including the registration and completion of Nasus Pharma’s initial public offering on Form F-1 and subsequent updates on the partial exercise of the underwriters’ over-allotment option. These disclosures outline the company’s stated use of proceeds, such as funding further development of its intranasal epinephrine program and general corporate purposes, and provide detail on underwriting arrangements.
As a foreign private issuer, Nasus Pharma is required to file an annual report on Form 20-F, and it supplements this with periodic Form 6-K submissions when it releases press statements or corporate presentations that are material to investors. Some 6-K filings incorporate press releases, such as the CEO’s letter to shareholders or news of regulatory clearances, directly as exhibits.
On this page, users can review Nasus Pharma’s SEC filings as they are made available through the EDGAR system. Stock Titan enhances access by pairing filings with AI-powered summaries that help explain key sections, highlight clinical and financial themes, and make lengthy documents such as financial statements and management analyses easier to understand. Investors can quickly identify filings related to clinical progress of NS002, leadership and governance changes, capital raising activities, and significant collaboration agreements.
Nasus Pharma Ltd reports beneficial ownership disclosures. Funicular Funds, LP; Cable Car Capital, LP; and Jacob Ma-Weaver each report beneficial ownership of 612,913 Ordinary Shares, representing 5.2% of the class. The calculation uses 11,710,808 Shares outstanding as of March 27, 2026 per the Post-Effective Amendment No. 1 to Form F-1. Cable Car Capital, LP is identified as general partner of Funicular Funds and Ma-Weaver is the managing member and therefore may be deemed the beneficial owner of the shares held by Funicular Funds.
Nasus Pharma Ltd Chief Executive Officer Dan Benjamin Teleman reported an open-market purchase of 15,000 Ordinary Shares of the company at $2.04 per share. Following this transaction, he directly holds 21,246 Ordinary Shares, indicating a higher personal equity stake in the business.
Nasus Pharma Ltd executive Rubin Eyal, the Chief Financial Officer and EVP, filed an initial ownership report showing he holds unvested share options over 85,648 and 40,549 ordinary shares. These options, all at an exercise price of $7.56 per share, were granted on November 20, 2025 and expire on November 20, 2035.
As of March 18, 2026, all 126,197 options remain outstanding and unvested under time-based vesting schedules, and the filing does not report any share purchases or sales.
Nasus Pharma Ltd director David Silberman filed an initial ownership report showing a stock option position rather than a recent trade. He holds options to buy 10,000 Ordinary Shares at an exercise price of $5.38 per share, granted on December 11, 2025. The grant vests at 2.0833% of the total each month after that date. As of March 18, 2026, all 10,000 options remain outstanding, with 625 options vested and exercisable, and the options are scheduled to expire on December 11, 2035.
Nasus Pharma Ltd director and CEO Dan Benjamin Teleman filed an initial statement of ownership. He holds options over 318,855 Ordinary Shares, granted at an exercise price of $6.046 per share, expiring on January 7, 2035, with 132,845 options already vested as of March 18, 2026. He also directly owns 6,246 Ordinary Shares.
Nasus Pharma Ltd director Shacham Sharon has reported existing option holdings in the company. The filing shows options to purchase 10,000 Ordinary Shares, granted on December 11, 2025, vesting 2.0833% monthly. As of March 18, 2026, all 10,000 options remain outstanding, with 625 vested and exercisable at an exercise price of $5.38 per share, expiring on December 11, 2035.
Nasus Pharma Ltd founder and Executive Chairman Udi Gilboa has filed an initial Form 3 detailing his ownership in the company. He reports direct ownership of 1,919,281 Ordinary Shares and indirect ownership of 5,195 Ordinary Shares held by Formulex Pharma Innovations Ltd., where he is a beneficial owner. He also holds Warrants that are immediately exercisable to purchase up to 17,970 Ordinary Shares at an exercise price of $6.53 per share. These Warrants were issued on February 13, 2026 and will expire on the earlier of two years from issuance or 30 trading days after Nasus announces top-line results of its NS002 Pivotal Study.
Nasus Pharma Ltd director Ronnie Hershman filed an initial ownership report showing existing equity and derivative holdings in the company. The filing lists options to purchase 63,017 Ordinary Shares at an exercise price of $4.297 per share, fully vested and exercisable until May 6, 2030. It also shows warrants to purchase up to 17,970 Ordinary Shares at $6.53 per share, issued February 13, 2026, and exercisable until the earlier of two years from issuance or 30 trading days after announcement of top-line results from the NS002 Pivotal Study. Indirect holdings include 909,156 Ordinary Shares and the warrants through Hershman Holdings, LLC and 429,307 Ordinary Shares through Phoenix Solutions Ltd., which Hershman may be deemed to beneficially own.
Nasus Pharma Ltd director, Chief Development Officer and founder Dr. Dalia Megiddo filed an initial statement of beneficial ownership of securities. She reports beneficial ownership of 1,888,873 Ordinary Shares held directly.
She also reports indirect beneficial ownership of 5,195 Ordinary Shares held by Formulex Pharma Innovations Ltd, where she is a beneficial owner and may be deemed to beneficially own those shares as well. The filing does not reflect any recent share purchases or sales, only current holdings.